MAZE vs MBX: fair value comparison
Maze Therapeutics, Inc. and MBX Biosciences, Inc. · Updated 2026-10-19
MAZE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. MBX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MAZE currently ranks higher by quality score.
| MAZE | MBX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $27.53 | $49.61 |
| 12-month range | $22.39–$51.84 | $16.13–$70.70 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #249 of 301 Healthcare | #250 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: MAZE fair value analysis · MBX fair value analysis